Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KWLZ-9e
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
KWLZ-9e: sourced facts only. name: "The biological evaluation showed that the optimized compound KWLZ-9e displayed potential GSK-3β (IC50 = 0.25 μM) inhibitory activity and neuroprotective capacity." [PMID:37172476]; target: "The biological evaluation showed that the optimized compound KWLZ-9e displayed potential GSK-3β (IC50 = 0.25 μM) inhibitory activity and neuroprotective capacity." [PMID:37172476]; developer: "Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, China." [PMID:37172476]; stage: "We also confirmed that KWLZ-9e could ameliorate learning and memory impairments in vivo model of AD." [PMID:37172476]
02
Targets
GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on KWLZ-9e.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KWLZ-9e.